On The Radar – 11th Edition
By
The Department of Justice is increasingly targeting PBMs and pharmacies under the False Claims Act, with enforcement actions tied to spread pricing, inflated claims, and dispensing violations. Recent settlements involving CVS Caremark and Walgreens signal that enforcement is expanding beyond manufacturers to include intermediaries of all sizes.
➡ Why it matters: PBM contracting and oversight now carry real legal and financial risk for plans that lack transparency and controls.
The first wave of IRA-negotiated drug prices offers modest discounts, while some plans are seeing higher bids and tighter utilization management. High-cost Medicare members benefit most from the $2,000 out-of-pocket cap, while others may face higher deductibles and coinsurance.
➡ Why it matters: Price negotiation alone does not guarantee lower plan costs, especially when rebate dynamics remain unchanged.
New legislation aims to reduce frivolous ERISA lawsuits while increasing PBM transparency and accountability. At the same time, the Department of Labor continues to explore PBM fee disclosure under existing ERISA rules.
➡ Why it matters: Fiduciary responsibility for pharmacy benefits is expanding through both legislation and regulation.
Formularies are increasingly shaped by rebate incentives rather than lowest net cost, leading to higher tiers for some generics and more frequent drug exclusions. Specialty drug sourcing and PBM-affiliated biosimilars add further complexity.
➡ Why it matters: Complexity at the formulary level increases confusion, disrupts access, and undermines cost control efforts.
Competition among manufacturers and PBMs has driven faster GLP-1 price reductions than regulatory timelines. Consumer demand and formulary pressure continue to influence pricing decisions in real time.
➡ Why it matters: Market dynamics remain a powerful force in drug pricing, often moving faster than policy.
Recent drug pricing initiatives have done more to illuminate the true mechanics of the system than to immediately lower costs. High list prices persist due to rebate-driven incentives that obscure real pricing from patients and plans.
➡ Why it matters: Transparency is becoming the catalyst for long-term reform, even when short-term savings are limited.
The orphan drug market is projected to more than double by 2034, driven by regulatory incentives and advanced therapies. High development costs and limited patient populations continue to challenge affordability.
➡ Why it matters: Rare disease therapies will remain a major contributor to specialty spend growth.
An op-ed highlights how PBM profit models tied to rebates and spread pricing inflate costs for patients and plans, while independent pharmacies face declining reimbursement and closures.
➡ Why it matters: Public pressure is aligning with regulatory action to challenge PBM business practices.
Rising premiums and out-of-pocket costs are forcing insured Americans to delay preventive care, with long-term consequences for health outcomes and financial stability.
➡ Why it matters: Benefit design that discourages early care often leads to higher downstream costs.
High-deductible plans are forcing patients with chronic conditions to ration medications and skip routine care, increasing the risk of hospitalization and irreversible complications.
➡ Why it matters: Cost shifting can undermine both clinical outcomes and workforce productivity.
Surveys show employers are prioritizing pharmacy oversight, transparency compliance, and data-driven strategies such as AI and analytics to manage accelerating medical and drug spend.
➡ Why it matters: Cost containment is no longer optional. It is a core employer strategy.
Final Thoughts
This edition underscores a critical shift. Pharmacy benefits are no longer just a cost line item but a legal, fiduciary, and operational risk area. Employers who demand transparency, audit rights, and aligned incentives are best positioned to protect both their plans and their people.
We’ll be back in two weeks with more news you need to know. If you’d like a custom analysis or want to explore SHARx program options for your clients, contact us!
Stay Connected with SHARx
Subscribe to our newsletter for monthly updates from our CEO, curated industry news, insights from our in-house pharmacist, the latest blog posts, and more. Just fill out the form to stay informed.
Newsletter Sign-up
Be the first to learn what’s new with SHARx.